Celcuity To Present at Upcoming Needham and Stifel Investor ConferencesGlobe Newswire • 12 days ago
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Share to Feed
Key Insights Institutions' substantial holdings in Celcuity implies that they have significant influence over the...
Celcuity (NASDAQ:CELC - Free Report) had its price target hoisted by Needham Company LLC from $23.00 to $24.00 in a research report released on Thursday, Benzinga reports. Needham Company...
Celcuity (NASDAQ:CELC - Get Free Report) had its price objective increased by equities researchers at Needham & Company LLC from $23.00 to $24.00 in a research report issued to clients and investors...
Celcuity (NASDAQ:CELC Free Report) had its target price lifted by Craig Hallum from $20.00 to $25.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy...
Celcuity Inc. (CELC) has disclosed a new risk, in the Share Price & Shareholder Rights category. Celcuity Inc. faces significant financial risks as...
This is a signal that CELC's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a Bullish indicator signaling CELC's price could rise from here. Traders may explore going long the stock or buying call options...
This price move could be a signal that CELC may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC Research Report) and Erasca (ERAS...